PMID- 35224108
OWN - NLM
STAT- MEDLINE
DCOM- 20220329
LR  - 20220502
IS  - 2314-6753 (Electronic)
IS  - 2314-6745 (Print)
VI  - 2022
DP  - 2022
TI  - Impacts of Sodium/Glucose Cotransporter-2 Inhibitors on Circulating Uric Acid 
      Concentrations: A Systematic Review and Meta-Analysis.
PG  - 7520632
LID - 10.1155/2022/7520632 [doi]
LID - 7520632
AB  - BACKGROUND: Several trials have assessed the antihyperglycemic effects of 
      sodium/glucose cotransporter-2 inhibitors (SGLT2i) in patients with type 2 
      diabetes mellitus (T2DM). We conducted a quantitative analysis to assess the 
      impact of SGLT2is on serum uric acid (SUA) in patients with T2DM. METHODS: 
      Placebo-controlled trials published before 13 August 2021 were identified by 
      searching PubMed, Embase, Web of Science, and Scopus. The intervention group 
      received SGLT2i as monotherapy or add-on treatment, and the control group 
      received a placebo that was replaced with SGLT2i. Clinical trials providing 
      changes in SUA were included. The mean change of SUA, glycated hemoglobin 
      (HbA1c), fasting plasma glucose (FPG), and body weight were calculated (PROSPERO 
      CRD42021287019). RESULTS: After screening of 1172 papers, 59 papers were included 
      in the systematic review. A total of 55 trials (122 groups) of 7 types of SGLT2i 
      on patients with T2DM were eligible for meta-analysis. All SGLT2is significantly 
      decreased SUA levels compared with the placebo groups: empagliflozin mean 
      difference (MD) = -40.98 mumol/L, 95% CI [-47.63, -34.32], dapagliflozin MD = 
      -35.17 mumol/L, 95% CI [-39.68, -30.66], canagliflozin MD = -36.27 mumol/L, 95% CI 
      [-41.62, -30.93], luseogliflozin MD = -24.269 mumol/L, 95% CI [-33.31, -15.22], 
      tofogliflozin MD = -19.47 mumol/L, 95% CI [-27.40, -11.55], and ipragliflozin MD = 
      -18.85 mumol/L, 95% CI [-27.20, -10.49]. SGLT2i also decreased FPG, body weight, 
      and HbA1c levels. SUA reduction persisted during long-term treatment with SGLT2i 
      (except for empagliflozin), while the SUA reduction was affected by the duration 
      of diabetes. CONCLUSIONS: SGLT2i can be a valid therapeutic strategy for patients 
      with T2DM and comorbid hyperuricemia. Besides reducing FPG, body weight, and 
      HbA1c, SGLT2i can significantly decrease SUA levels compared to placebo (Total MD 
      = -34.07 mumol/L, 95% CI [-37.00, -31.14]).
CI  - Copyright (c) 2022 Abolfazl Akbari et al.
FAU - Akbari, Abolfazl
AU  - Akbari A
AD  - Student Research Committee, Faculty of Medicine, Mashhad University of Medical 
      Sciences, Mashhad, Iran.
FAU - Rafiee, Mahdi
AU  - Rafiee M
AD  - Student Research Committee, Faculty of Medicine, Mashhad University of Medical 
      Sciences, Mashhad, Iran.
FAU - Sathyapalan, Thozhukat
AU  - Sathyapalan T
AD  - Department of Academic Diabetes, Endocrinology and Metabolism, Hull York Medical 
      School, University of Hull, Hull, UK.
FAU - Sahebkar, Amirhossein
AU  - Sahebkar A
AUID- ORCID: 0000-0002-8656-1444
AD  - Applied Biomedical Research Center, Mashhad University of Medical Sciences, 
      Mashhad, Iran.
AD  - Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad 
      University of Medical Sciences, Mashhad, Iran.
AD  - Department of Medical Biotechnology and Nanotechnology, Faculty of Medicine, 
      Mashhad University of Medical Sciences, Mashhad, Iran.
AD  - Department of Biotechnology, School of Pharmacy, Mashhad University of Medical 
      Sciences, Mashhad, Iran.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20220217
PL  - England
TA  - J Diabetes Res
JT  - Journal of diabetes research
JID - 101605237
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Glucosides)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 0 (Thiophenes)
RN  - 0SAC974Z85 (Canagliflozin)
RN  - 1ULL0QJ8UC (dapagliflozin)
RN  - 268B43MJ25 (Uric Acid)
RN  - 3N2N8OOR7X (ipragliflozin)
RN  - HDC1R2M35U (empagliflozin)
SB  - IM
MH  - Benzhydryl Compounds/metabolism/pharmacology
MH  - Canagliflozin/metabolism/pharmacology
MH  - Glucosides/metabolism/pharmacology
MH  - Humans
MH  - Hypoglycemic Agents/metabolism/pharmacology/therapeutic use
MH  - Sodium-Glucose Transporter 2 Inhibitors/metabolism/*pharmacology/therapeutic use
MH  - Thiophenes/metabolism/pharmacology
MH  - Uric Acid/*metabolism
PMC - PMC8872662
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2022/03/01 06:00
MHDA- 2022/03/30 06:00
PMCR- 2022/02/17
CRDT- 2022/02/28 05:40
PHST- 2021/10/20 00:00 [received]
PHST- 2022/01/24 00:00 [accepted]
PHST- 2022/02/28 05:40 [entrez]
PHST- 2022/03/01 06:00 [pubmed]
PHST- 2022/03/30 06:00 [medline]
PHST- 2022/02/17 00:00 [pmc-release]
AID - 10.1155/2022/7520632 [doi]
PST - epublish
SO  - J Diabetes Res. 2022 Feb 17;2022:7520632. doi: 10.1155/2022/7520632. eCollection 
      2022.